Close

Lenti-SARS-CoV TCR (Cysteine-modified)-VP (VP-TCR-C474)

The ready-to-use lentiviral particles of Lenti-SARS-CoV TCR (Cysteine-modified)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of Human TCR will be driven by a CMV promotor. The target gene of TCR packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Specifications

  • Type of Therapeutics
  • T cell receptor
  • Target
  • SARS-CoV
  • Promotor
  • CMV
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • SARS

Target

  • Introduction
  • The SARS coronavirus, sometimes shortened to SARS-CoV, is the virus that causes severe acute respiratory syndrome (SARS). On April 16, 2003, following the outbreak of SARS in Asia and secondary cases elsewhere in the world, the World Health Organization (WHO) issued a press release stating that the coronavirus identified by a number of laboratories was the official cause of SARS.
  • Alternative Names
  • API4; EPR-1; BIRC5; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; cancer

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.